These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12069439)

  • 1. ASSENT-3: implications for future trial design and clinical practice.
    Van de Werf F
    Eur Heart J; 2002 Jun; 23(12):911-2. PubMed ID: 12069439
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of tirofiban for failed thrombolysis during acute myocardial infarction.
    Vetrano A; Carotenuto R; Corsini F; Schioppa M; Martone A; Melorio S; Sideri F; Romano S; Chieffo C; Corsini G
    Am J Cardiol; 2004 Apr; 93(7):914-6. PubMed ID: 15050497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological reperfusion in acute myocardial infarction after ASSENT 3 and GUSTO V.
    Ferreira D
    Rev Port Cardiol; 2003; 22(7-8):1005-9. PubMed ID: 14587168
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombolytic therapy: new dimensions 2009.
    Guha S; Mukherjee S; Hema MB
    Indian Heart J; 2009; 61(5):415-21. PubMed ID: 20635755
    [No Abstract]   [Full Text] [Related]  

  • 5. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
    Ray KK; Morrow DA; Gibson CM; Murphy S; Antman EM; Braunwald E
    Eur Heart J; 2005 Mar; 26(5):440-6. PubMed ID: 15673542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
    Montalescot G
    Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue plasminogen activator does not benefit most eligible patients with stroke.
    Lansberg MG; Schwartz NE
    Arch Neurol; 2009 Apr; 66(4):540-1; author reply 541. PubMed ID: 19364946
    [No Abstract]   [Full Text] [Related]  

  • 10. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPIIb/IIIa inhibitor-induced dethrombosis.
    Furman MI; Frelinger AL; Michelson AD
    J Thromb Thrombolysis; 2004 Aug; 18(1):11-7. PubMed ID: 15744548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction.
    Lincoff AM
    Rev Cardiovasc Med; 2002; 3 Suppl 1():S13-9. PubMed ID: 12439432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention versus thrombolysis: the definite management of st elevation myocardial infarction.
    Martinez-Ojeda J; Martinez-Toro J
    Bol Asoc Med P R; 2005; 97(4):308-14. PubMed ID: 16599071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
    Shimpi RA
    J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
    [No Abstract]   [Full Text] [Related]  

  • 15. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from clinical trials on ST-elevation myocardial infarction in a historic perspective with some pathophysiological aspects.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2003 Dec; 37(6):316-23. PubMed ID: 14668180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombolysis in stroke: still not ready for community hospital use by emergency physicians.
    McNamara RM
    Ann Emerg Med; 2009 Sep; 54(3):339-41. PubMed ID: 19695417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.